Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03432286 · ClinicalTrials.gov registry record · Phase 3
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
A Phase 3 study of Episodic Migraine, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 533
- Enrollment target
- 20
- Study locations
NCT03432286: Active Phase 3 study of Episodic Migraine, sponsored by Eli Lilly and Company.
NCT03432286 is a Phase 3 study of Episodic Migraine that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 533 participants, above the 456-participant average among 13 other Episodic Migraine trials with a reported enrollment target (17% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03432286, a Phase 3 study of Episodic Migraine, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 533 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Primary Outcome
Change from baseline in the number of monthly migraine headache days
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Galcanezumab
Study Locations (20)
Florida
- Clinical Neuroscience Solutions, Inc. dba CNS Healthcare - Jacksonville
- University of Miami Don Suffer Clinical Research Building - Miami
- Ezy Medical Research - Miami Lakes
- Clinical Neuroscience Solutions - Orlando
- Avanza Medical Research Center - Pensacola
- USF Health - Tampa
- Premiere Research Institute at Palm Beach Neurology - West Palm Beach
Arizona
- 21st Century Neurology, a Division of Xenoscience, Inc. - Phoenix
- Phoenix Children's Hospital - Phoenix
- Center for Neurosciences - Tucson
Idaho
- Medical Research Partners - Ammon
- Elite Clinical Trials - Blackfoot
- Northwest Clinical Trials - Boise
California
- Miller Children's & Women's Hospital Long Beach - Long Beach
- Wr-McCr, Llc - San Diego
Georgia
- Clinical Integrative Research Center of Atlanta, LLC - Atlanta
- Meridian Clinical Research, LLC - Savannah
Alabama
- Rehabilitation & Neurological Services - Huntsville
Colorado
- Children's Hospital Colorado - Aurora
Illinois
- Inpatient Pharmacy - Hoffman Estates
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 533 participants |
| Start Date | 2018-03-14 |
| Est. Completion | 2026-11 |
| Phase | Phase 3 |
What the registry record for NCT03432286 still lists
NCT03432286 is an interventional study that assigns participants to a tested intervention. The registered 533 participants enrollment target is mid-sized for trials with a published cap, above the 456-participant average among 13 other Episodic Migraine trials with a reported enrollment target (17% higher).
The record links to 1 condition, with Episodic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03432286 names 20 study sites across 8 states, led by Florida, Arizona, Idaho.
Frequently Asked Questions
What is clinical trial NCT03432286 about?
NCT03432286 is a clinical study titled "A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine". The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine he...
What is the current status of trial NCT03432286?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 533 participants. The study started on 2018-03-14. Estimated completion is 2026-11.
What conditions does trial NCT03432286 study?
This clinical trial studies the following conditions: Episodic Migraine.
What interventions are being tested in trial NCT03432286?
The interventions under investigation include: Placebo (DRUG), Galcanezumab (DRUG).
Who is sponsoring clinical trial NCT03432286?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03432286 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Episodic Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03432286's enrollment target sits among peer trials
533 8th of 13 higher than 6 of 13 other Episodic Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Episodic Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
RECRUITING · Phase 3
-
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
RECRUITING · Phase 3
-
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
ACTIVE NOT RECRUITING · Phase 3
-
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
COMPLETED · Phase 3
-
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT05793151 · 532 participants · NA
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
- NCT06378866 · 532 participants · Phase 2
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI